Siegfried Holding (SFZN) Stock Overview
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SFZN Community Fair Values
See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeSiegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 78.70 |
| 52 Week High | CHF 101.60 |
| 52 Week Low | CHF 68.50 |
| Beta | 0.79 |
| 1 Month Change | 1.29% |
| 3 Month Change | -17.76% |
| 1 Year Change | -20.42% |
| 3 Year Change | 9.00% |
| 5 Year Change | -4.32% |
| Change since IPO | 935.53% |
Recent News & Updates
SFZN: Fair Value Reset Will Put Greater Emphasis On Execution Risks
Analysts now see fair value for Siegfried Holding at CHF 85.00, down from CHF 90.00. This aligns with recent price target cuts, such as the move from CHF 108 to CHF 96, and reflects updated assumptions on growth, profitability and discount rates.SFZN: Lower Street Expectations Will Support Future Upside Potential
Analysts now see Siegfried's fair value aligning with a lower Street view, with a key price target reset to CHF 96 from CHF 108 as they highlight more balanced expectations following the recent downgrade. Analyst Commentary Recent Street commentary around Siegfried reflects a more cautious stance, with price targets reset and ratings adjusted to align expectations more closely with current execution and valuation risks.SFZN: Reset Expectations And Recent Downgrade Will Support Future Upside Potential
Analysts have trimmed their price target for Siegfried Holding by CHF 3.60 to CHF 104.60, reflecting updated assumptions for fair value, discount rate and earnings profile following recent research. This includes a reduced CHF 96 target from RBC Capital and a downgrade in their rating.Recent updates
Shareholder Returns
| SFZN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0.8% | 0.4% | -0.3% |
| 1Y | -20.4% | -15.4% | 7.0% |
Return vs Industry: SFZN underperformed the Swiss Life Sciences industry which returned -15.4% over the past year.
Return vs Market: SFZN underperformed the Swiss Market which returned 7% over the past year.
Price Volatility
| SFZN volatility | |
|---|---|
| SFZN Average Weekly Movement | 4.9% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 8.3% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: SFZN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: SFZN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,891 | Marcel Imwinkelried | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition.
Siegfried Holding AG Fundamentals Summary
| SFZN fundamental statistics | |
|---|---|
| Market cap | CHF 3.45b |
| Earnings (TTM) | CHF 168.66m |
| Revenue (TTM) | CHF 1.33b |
Is SFZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFZN income statement (TTM) | |
|---|---|
| Revenue | CHF 1.33b |
| Cost of Revenue | CHF 973.84m |
| Gross Profit | CHF 353.99m |
| Other Expenses | CHF 185.34m |
| Earnings | CHF 168.66m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 21, 2026
| Earnings per share (EPS) | 3.85 |
| Gross Margin | 26.66% |
| Net Profit Margin | 12.70% |
| Debt/Equity Ratio | 51.0% |
How did SFZN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 05:54 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Siegfried Holding AG is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |
| Vineet Agrawal | Citigroup Inc |